Kogniz, Inc. MARCS-CMS 613569 — August 16, 2024

CLOSEOUT LETTER

• Product: Medical Devices

---

• Recipient: Jed Putterman; Co-CEO; Kogniz, Inc.; 611 Gateway Boulevard; Suite 120; South San Francisco, CA 94080; United States; jed@kogniz.com

• Issuing Office: Center for Devices and Radiological Health; United States

---

Dear Jed Putterman:

The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter (CMS #613569, dated March 4, 2021). Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed in the future.

Sincerely,
/S/
for
Kellie B. Kelm, Ph.D.
Acting Director
OHT 3: Office of GastroRenal, ObGyn,
General Hospital and Urology Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health